抗腫瘍インドール-カルコン誘導体に関する最近の進歩:ミニレビュー
Guangyuan Liu1, Yawei Han1, Yuhao Wei1
1Hubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, No. 13 Hangkong Road, Wuhan 430030, China.
European journal of pharmacology
|December 21, 2025
まとめ
インドール-カルコン誘導体は、チューブリンやDNAなどの主要な分子を標的とすることにより、強力な抗がん活性を示す。このレビューでは、それらの構造、標的、およびプロテオリシス標的キメラ(PROTAC)技術を含むがん治療における可能性を探る。
科学分野:
- 医薬品化学
- 有機化学
- 薬理学
背景:
- カルコン誘導体は、そのα、β-不飽和ケトン構造により、抗がんおよび抗炎症特性を持っています。
- インドールモチーフは、抗がん効果を含む多様な生物学的活性を持つ既知の薬理活性基です。
- インドールとカルコンの骨格を組み合わせることは、抗がん効果を高めるための相乗的アプローチを提供します。
研究 の 目的:
- がん治療のためのインドール-カルコン誘導体の開発における最近の進歩をレビューすること。
- これらの化合物の多様な構造的枠組みと構造活性相関を調べること。
- それらの分子標的を分析し、プロテオリシス標的化キメラ(PROTAC)技術の応用を探求すること。
主な方法:
- インドール-カルコン誘導体に関する最近の研究の文献レビュー。
- 構造修飾とその生物学的活性への影響の分析。
- チューブリン、チオレドキシン還元酵素(TrxR)、および炭酸脱水酵素IX(CA IX)などの分子標的の調査。
主要な成果:
- インドール-カルコン誘導体は、様々な分子標的を介して強力な抗がん効果を発揮します。
- 特定の構造修飾は、異なる種類のがんに対するそれらの有効性を高めます。
- プロテオリシス標的化キメラ(PROTAC)技術は、がん治療における標的タンパク質分解に有望です。
結論:
- インドール-カルコン誘導体は、有望な抗がん剤クラスを表します。
- 構造活性相関と分子標的の理解は、それらの治療的可能性を最適化するために重要です。
- PROTAC技術の統合は、がん治療のための新しい標的タンパク質分解戦略につながる可能性があります。
さらに関連する動画
関連する概念動画
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
518
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
518
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
567
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
567
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
787
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
787
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K


